BioRestorative Therapies announces preliminary data from BRTX-100 trial in cLDD

BioRestorative Therapies (BRTX) announced that preliminary 26-, 52- and 104-week blinded preliminary data from the first 15 patients with chronic lumbar disc disease enrolled in the ongoing Phase 2 clinical trial of BRTX-100 was recently presented by Francisco Silva, Vice President of Research and Development, at the International Society for Cell & Gene Therapy 2025 Annual Meeting. No serious adverse events were reported, and there was no dose limiting toxicity at 26-104 weeks. The U.S. Food and Drug Association is requiring at least a greater than 30% improvement in both Oswestry Disability Index and Visual Analog Scale; ongoing clinical data demonstrates trends greater than 30% improvements in both measures. The following is breakdown of the percentage of subjects that had both a greater than 50% improvement in function, as measured by ODI, and a greater than 50% decrease in pain, as measured by VAS.